Aplicación YC de GEn1E Lifesciences

Summer 2019Active

GEn1E Lifesciences pasó por Y Combinator en el batch Summer 2019 como una empresa de Healthcare. Abajo: qué hace la empresa, quién la fundó y su aplicación a YC, reconstruida pregunta por pregunta en el formulario real de YC.

Batch YC: Summer 2019
Industria: HealthcareTherapeutics
Estado: Active
Lanzado: 2022

Fundadores

Ritu LalFounder

Lo que hace GEn1E Lifesciences

GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. We develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. Our team is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities - creating novel therapeutics at an unprecedented pace. Our AI platform has enabled us to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Our AI platform enables tremendous pace and capital efficiency as demonstrated by our progress in ~2 years with seed capital - a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. The team at GEn1E has decades of experience in drug development and machine learning. We graduated from YCombinator and Stanford-StartX in late 2019. We are based in Palo Alto, CA.

Aplicación YC de GEn1E Lifesciences, reconstruida

Solicitud de Y Combinator

GEn1E Lifesciences, batch Summer 2019. Las preguntas reales del formulario, respondidas con datos públicos.

Founders2
Company7
Progress7
Idea4
Equity3
Curious2
Batch Preference1

Company

Company name

GEn1E Lifesciences

Describe what your company does in 50 characters or less.

AI platform accelerating therapies for rare diseases

What is your company going to make? Please describe your product and what it does or will do.

We are building an AI platform that speeds up discovery and development of novel immunomodulatory therapies targeting multiple mechanisms at once. Our platform identifies and optimizes protein therapies for rare and inflammatory diseases with no current treatments. We've already developed a lead candidate for ARDS and a pipeline of 21+ selective immunomodulators.

Where do you live now, and where would the company be based after YC?

We live in Palo Alto, CA, and the company is based here.

Explain your decision regarding location.

Palo Alto puts us at the center of biotech and AI innovation, with access to top talent, investors, and collaborators. It's also where we're rooted personally and professionally.

21 respuestas más en la aplicación completa

están en la versión completa. Crea una cuenta gratuita para abrirla en YC Insights, junto a cada otro batch de YC.

Ver aplicación completa

Preguntas Frecuentes

¿Es esta la aplicación YC real de GEn1E Lifesciences?

No. Y Combinator mantiene privadas las aplicaciones enviadas. Esta es una reconstrucción: las preguntas reales del formulario de YC, respondidas a partir de los datos públicos de GEn1E Lifesciences (notas de lanzamiento, antecedentes de fundadores, descripción del producto). Muestra cómo una empresa como GEn1E Lifesciences se presentaría a YC, no el texto que enviaron.

¿En qué batch de YC estuvo GEn1E Lifesciences?

GEn1E Lifesciences formó parte del batch Summer 2019 de Y Combinator.

¿Quién fundó GEn1E Lifesciences?

GEn1E Lifesciences fue fundado por Ritu Lal.

¿A qué se dedica GEn1E Lifesciences?

AI platform accelerating therapies for rare & inflammatory diseases.

¿Cómo leo la aplicación completa reconstruida?

Crea una cuenta gratuita de Round Funded. La versión completa de 26 respuestas de la aplicación de GEn1E Lifesciences, y de cada otro batch de YC, está en YC Insights.